Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia

B SHANGHAI, May 6, 2026 /PRNewswire/ — Alebund Pharmaceuticals (Jiangsu) Limited (“Alebund” or the “Company”), an integrated biopharmaceutical company focusing on developing innovative therapies for…
posteditor
posteditor
Articles: 21727

Other News